Accell Evo3 is said to be the latest generation in demineralized bone matrix and is composed of an optimized blend of particulate demineralized bone matrix (DBM), the proprietary Accell bone matrix (ABM), and a unique poloxamer reverse phase medium. The poloxamer reverse phase medium is a thermo-reversible carrier that thickens at body temperature and is more flowable at room temperature.
Accell Evo3 has been specifically formulated to provide surgeons with the best possible intraoperative handling characteristics for proper utilization of the graft material, and is marketed in combination with a new custom designed open bore syringe, the company said.
According to the company, Accell Evo3 may be used as a bone graft extender in the spine, extremities and pelvis or as bone void filler for the extremities and pelvis, and may replace the need to harvest bone graft material from the iliac crest, thus sparing the patient additional surgery and postoperative pain.
Brian Larkin, president of Integra NeuroSciences, said: “Accell Evo3 is truly an evolutionary advance in DBM technology that will separate it from the competition and provide a competitive alternative to other commercially available graft materials. Accell Evo3 confirms Integra OrthoBiologics’s commitment to drive innovation in bone fusion and healing.”